US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Ready Capital Corp

25.04

0.0000

Volume:- -

Turnover:- -

Market Cap:4.11B

PE:-12.77

High:25.04

Open:25.04

Low:25.04

Close:25.04

52wk High:26.87

52wk Low:23.97

Shares:164.33M

Float Shares:164.33M

Volume Ratio:- -

T/O Rate:- -

Dividend:1.44

Dividend Rate:5.74%

EPS(TTM):-1.9610

ROE:-13.30%

ROA:-2.87%

PB:2.47

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates

Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough

Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

Trevi Therapeutics to Participate in Upcoming March Conferences

Exelixis: Welireg Competition Tempers RCC Upside but Embedded Cabozantinib Franchise Supports Hold Rating

Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)

Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Interim Results for the six months ended 31 October 2025

ATR Plane Missing Near Makassar with 10 on Board

Press Release: Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting

Kura Oncology Reports Third Quarter 2025 Financial Results

Exelixis’s Strategic Positioning and Market Prospects Justify Buy Rating Amid RCC Treatment Dynamics

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

The Ultimate Biotech Stock to Buy With $50 Right Now

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RCC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RCC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCC\",,,,,undefined,":{"symbol":"RCC","market":"US","secType":"STK","nameCN":"Ready Capital Corp","latestPrice":25.04,"timestamp":1772830800000,"preClose":25.04,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":164327000,"shares":164327000,"eps":-1.961,"marketStatus":"Market Closed","change":0,"latestTime":"03-06 16:00:00 EST","open":25.04,"high":25.04,"low":25.04,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.961,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":25.04,"dividendRate":0.05741,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCC\",,,,,undefined,":{"symbol":"RCC","floatShares":164327000,"roa":"-2.87%","roe":"-13.30%","lyrEps":0,"shares":164327000,"dividePrice":1.437535,"high":25.04,"amplitude":0,"preClose":25.04,"low":25.04,"week52Low":23.97,"pbRate":"2.47","psRate":"-38.40","week52High":26.87,"institutionHeld":0,"latestPrice":25.04,"eps":-1.961,"divideRate":0.05741,"volume":0,"delay":0,"ttmEps":-1.961,"open":25.04,"prevYearClose":25.05,"prevWeekClose":25.04,"prevMonthClose":24.92,"prevQuarterClose":25.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCC\",params:#limit:5,,,undefined,":[{"date":"2026-02-26","symbol":"RCC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772139600000,"name":null,"time":"Post Market","dateTimestamp":1772082000000,"actualEps":null},{"market":"US","date":"2026-02-17","symbol":"RCC","reason":null,"defaultRemindTime":1771338600000,"announcedDate":"2026-01-26","type":"delisting","dateTimestamp":1771304400000},{"date":"2026-01-15","symbol":"RCC","amount":0.3594,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-15","defaultRemindTime":1768487400000,"name":"Ready Capital Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-30","payableDate":"2026-01-15","currency":"USD","dateTimestamp":1768453200000,"payDate":"2026-01-30"},{"date":"2025-10-15","symbol":"RCC","amount":0.359375,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-15","defaultRemindTime":1760535000000,"name":"Ready Capital Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-30","payableDate":"2025-10-15","currency":"USD","dateTimestamp":1760500800000,"payDate":"2025-10-30"},{"date":"2025-07-15","symbol":"RCC","amount":0.35938,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-15","defaultRemindTime":1752586200000,"name":"Ready Capital Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-30","payableDate":"2025-07-15","currency":"USD","dateTimestamp":1752552000000,"payDate":"2025-07-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCC\",market:\"US\",,,undefined,":[{"executeDate":"2021-04-14","recordDate":"2021-04-15","paymentDate":"2021-04-30","value":0.3194444,"currency":"USD"},{"executeDate":"2021-07-14","recordDate":"2021-07-15","paymentDate":"2021-07-30","value":0.359375,"currency":"USD"},{"executeDate":"2021-10-14","recordDate":"2021-10-15","paymentDate":"2021-10-30","value":0.359375,"currency":"USD"},{"executeDate":"2022-01-13","recordDate":"2022-01-14","paymentDate":"2022-01-30","value":0.359375,"currency":"USD"},{"executeDate":"2022-04-13","recordDate":"2022-04-14","paymentDate":"2022-04-30","value":0.359375,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RCC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0.875,"sell":0.125,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.875,"analysts":8,"updateTime":1766120400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620682408","title":"Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2620682408","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620682408?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:05","pubTimestamp":1773777900,"startTime":"0","endTime":"0","summary":"Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough. On track to initiate a Phase 2b clinical trial for the treatment of patients with refractory chronic cough in the second quarter of 2026. Company ended 2025 with $188.3 million in cash, cash equivalents and marketable securities, with expected cash runway into 2028. Management to host a conference call and webcast today at 4:30 p.m. ET. NEW HAVEN, Conn., March 17, 2026  -- Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis , non-IPF interstitial lung disease , and refractory chronic cough , today announced financial results for the fourth quarter and year ended December 31, 2025, and provided business updates.overall alignment on the plan for the remai","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","TRVI","BK4585","LENZ","BK4588","TM","LABU","BK4604","BK4555","RCC","BK4007","BK4539","BK4099","BK4139"],"gpt_icon":0},{"id":"2618790966","title":"Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618790966","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618790966?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:05","pubTimestamp":1773173100,"startTime":"0","endTime":"0","summary":"Conference call and webcast to be held at 4:30 p.m. ETNEW HAVEN, Conn., March  10, 2026  (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company develop","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3253310/0/en/Trevi-Therapeutics-to-Report-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provide-Business-Updates-on-March-17-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","RCC","BK4007","BK4139"],"gpt_icon":0},{"id":"2618238886","title":"Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough","url":"https://stock-news.laohu8.com/highlight/detail?id=2618238886","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618238886?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:30","pubTimestamp":1773055800,"startTime":"0","endTime":"0","summary":"The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251724/0/en/Trevi-Therapeutics-Announces-Completion-of-End-of-Phase-2-Meeting-with-the-FDA-Gaining-Alignment-for-Its-Development-Program-for-Idiopathic-Pulmonary-Fibrosis-Related-Chronic-Cough.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","BK4588","BK4585","LABU","BK4139","RCC","LENZ"],"gpt_icon":0},{"id":"2617549895","title":"Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2617549895","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617549895?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:31","pubTimestamp":1772710260,"startTime":"0","endTime":"0","summary":"– KOMZIFTI (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, s","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/05/3249967/35186/en/Kura-Oncology-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCC","BK4505","KURA"],"gpt_icon":0},{"id":"2616330611","title":"Trevi Therapeutics to Participate in Upcoming March Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2616330611","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616330611?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:30","pubTimestamp":1772454600,"startTime":"0","endTime":"0","summary":"NEW HAVEN, Conn., March  02, 2026  (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigationaltherapyHaduvio(oral nalbuphine ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/02/3247261/0/en/Trevi-Therapeutics-to-Participate-in-Upcoming-March-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCC","BK4007","LENZ","BK4539","BK4139"],"gpt_icon":0},{"id":"2616310963","title":"Exelixis: Welireg Competition Tempers RCC Upside but Embedded Cabozantinib Franchise Supports Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2616310963","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616310963?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:16","pubTimestamp":1772453772,"startTime":"0","endTime":"0","summary":"Sean Laaman, an analyst from Morgan Stanley, maintained the Hold rating on Exelixis. The associated price target remains the same with $49.00. Sean...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/exelixis-welireg-competition-tempers-rcc-upside-but-embedded-cabozantinib-franchise-supports-hold-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/exelixis-welireg-competition-tempers-rcc-upside-but-embedded-cabozantinib-franchise-supports-hold-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RCC","EXEL"],"gpt_icon":0},{"id":"2614722974","title":"Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614722974","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614722974?lang=en_us&edition=fundamental","pubTime":"2026-02-25 08:30","pubTimestamp":1771979400,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Feb. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited  , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, announced that it has entered into a clinical collaboration agreement with Shanghai Junshi Biosciences Co., Ltd . Under the collaboration, the parties will jointly evaluate the synergistic therapeutic potential of Antengene's ATG-037, an oral small-molecule CD73 inhibitor, in combination with Junshi Biosciences' JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, in patients with solid tumors in Mainland China, with the goal of identifying clinical signals across multiple tumor types.","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-announces-clinical-collaboration-with-junshi-biosciences-to-explore-the-synergistic-potential-of-atg-037-oral-cd73-inhibitor-in-combination-with-js207-pd-1vegf-bsab-302695694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","IND.AU","LU0963586101.USD","IND","BK4187","BK4006","BK4023","LU1169590202.USD","CRS.AU","CRS","IE00B19Z4B17.USD","RCC","HCC","PD","ORR.AU","OS","BK7095","ORR","IE00B66KJ199.SGD","BK4097","LU2065731478.USD","IE00B7SZL793.SGD","IE0031619046.USD"],"gpt_icon":0},{"id":"2612575144","title":"Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2612575144","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612575144?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:30","pubTimestamp":1771331400,"startTime":"0","endTime":"0","summary":"Fireside chat with management on February 25, 2026, at 9:20 a.m. ETNEW HAVEN, Conn., Feb.  17, 2026  (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239122/0/en/Trevi-Therapeutics-to-Participate-in-the-Oppenheimer-36th-Annual-Healthcare-Life-Sciences-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","BK4137","BK4588","LENZ","RCC","LU0128526141.USD","BK4127","BK4539","XLV","BK4585","XBI","LU0029874061.USD","BK4581","LABU","BK4139","OPY","BK4007"],"gpt_icon":0},{"id":"2607115705","title":"Interim Results for the six months ended 31 October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2607115705","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607115705?lang=en_us&edition=fundamental","pubTime":"2026-01-29 15:00","pubTimestamp":1769670000,"startTime":"0","endTime":"0","summary":"OXFORD, United Kingdom, Jan.  29, 2026  (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBodyand Moditopeactive immunotherapies to treat cancer, today announces a business","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/29/3228196/0/en/Interim-Results-for-the-six-months-ended-31-October-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","MAR","IE00B95QR487.USD","BK4585","IND","LU2404859741.USD","RCC","GB00B4QBRK32.GBP","BK4142","LU0690374961.EUR","BK4211","GB00B4LPDJ14.GBP","IE00B1G9WX41.USD","OS","LU2404859667.USD","BK4588","EMA","IE00B45NX917.SGD","PFS","IE00BD0PCF45.HKD","BK4156","LU0690374615.EUR","IE00B0T0GQ85.USD","BK4081","BK4097","LU1718418525.SGD"],"gpt_icon":0},{"id":"2604847942","title":"ATR Plane Missing Near Makassar with 10 on Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2604847942","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604847942?lang=en_us&edition=fundamental","pubTime":"2026-01-17 19:41","pubTimestamp":1768650074,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta-An Indonesia Air Transport  ATR 42-500 plane, registered as PK-THT, lost contact while approaching Sultan Hasanuddin Airport, Makassar, on Saturday, January 17, 2026. The Directorate General of Civil Aviation received the report earlier today.Director General of Civil Aviation Lukman F. Laisa stated the aircraft was operated by IAT, holder of Air Operator Certificate  034. The aircraft, manufactured in 2000 with serial number 611, flew from Adi Sucipto Yogyakarta to Sultan Hasanuddin Makassar with Pilot in Command Capt. Andy Dahananto.\"At 04:23 UTC, the aircraft was directed by the ATC Makassar Area Terminal Service Center  to approach Runway 21,\" Lukman said in a written statement on Saturday, January 17, 2026.","market":"us","thumbnail":"https://statik.tempo.co/data/2026/01/17/id_1453844/1453844_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/01/17/id_1453844/1453844_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2081104/atr-plane-missing-near-makassar-with-10-on-board","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2081104/atr-plane-missing-near-makassar-with-10-on-board","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["ATC.AU","BK7081","RCC","IAT","ATR","BK7023","BK4126"],"gpt_icon":0},{"id":"2602515003","title":"Press Release: Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602515003","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602515003?lang=en_us&edition=fundamental","pubTime":"2026-01-12 18:37","pubTimestamp":1768214220,"startTime":"0","endTime":"0","summary":"-- Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 --. -- Fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion --. -- Presentation and webcast at J.P. Morgan 2026 Healthcare Conference tomorrow, Monday, January 12 at 5:15 p.m. PT / 8:15 p.m. ET --. Exelixis, Inc.  today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, works toward building a potential second commercial franchise with zanzalintinib and moves its earlier stage pipeline forward. As outlined at its December 2025 R&D Day, the company seeks to leverage its diverse pipeline and key clinical collaborations to build next-generation oncology franchises t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","R","BK4232","LU2065171311.SGD","BK4195","RCC","EXEL","BK4211","BK4213","BK4613","ORR","BK4116","CRC","BK4097","BK4585","OS","PFS","BK4560","LU2065171402.SGD","BK4022","BK4139","LU2065169927.USD","BK4548","LU0266512127.USD","BK4607","BK4554","LU2065170008.USD","LU2286300806.USD","LU0456854461.SGD","NET"],"gpt_icon":0},{"id":"2601882367","title":"Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T","url":"https://stock-news.laohu8.com/highlight/detail?id=2601882367","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601882367?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:30","pubTimestamp":1767879000,"startTime":"0","endTime":"0","summary":"1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Ce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215373/0/en/Allogene-Therapeutics-Positions-2026-as-a-Program-Defining-Year-for-Scalable-Real-World-Allogeneic-CAR-T.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","CAR","RCC","BK4539","BK4139","BK4230","BK4007","LENZ"],"gpt_icon":0},{"id":"2589841767","title":"Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2589841767","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589841767?lang=en_us&edition=fundamental","pubTime":"2025-12-06 11:11","pubTimestamp":1764990660,"startTime":"0","endTime":"0","summary":"Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201030/0/en/Toripalimab-Presents-Long-Term-Survival-Benefits-as-1st-line-Treatment-for-Advanced-Nasopharyngeal-Carcinoma-and-Esophageal-Squamous-Cell-Carcinoma-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","ITT","LU0054578231.USD","ORR","BK4006","LU0053671581.USD","LU0757428866.USD","IE0031619046.USD","IE00B19Z4B17.USD","RCC","PFS","BK4157","BK4161","GP","OS","BK4211","AEIS","LU1815336091.USD","BK4195","BK4149","IE00B7SZL793.SGD","BK4097","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2586299606","title":"HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586299606","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586299606?lang=en_us&edition=fundamental","pubTime":"2025-11-27 08:00","pubTimestamp":1764201600,"startTime":"0","endTime":"0","summary":"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov.  27, 2025  (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from severa","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/27/3195434/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-the-2025-ESMO-Asia-Congress-and-the-2025-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125154935.USD","BK4588","LU1244550577.SGD","LU0072461881.USD","BK4555","BK4560","BK4585","LU0130517989.USD","BK4504","BK4559","BK4534","LU0477156953.USD","LU0980610538.SGD","LU2286300806.USD","BK4023","BK4574","BK4561","LU0106831901.USD","BK4099","LU1244550221.USD","S","AG","BK4207","LU1244550494.USD","RCC","LU2360032135.SGD","BK4516","BK1191","LU0162691827.USD","LU0170899867.USD","IE00BSNM7G36.USD","LU1201861249.SGD","LU1267930227.SGD","LU0320765646.SGD","LU2462157665.USD","LU0648001328.SGD","ASH","LU0310800965.SGD","PD","LU2236285917.USD","BK1588","BK4109","00013","LU2456880835.USD","LU0128525689.USD","F","LU0130102774.USD","BK1587","BK4097","BK4539"],"gpt_icon":0},{"id":"2580780289","title":"Kura Oncology Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2580780289","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580780289?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:31","pubTimestamp":1762255860,"startTime":"0","endTime":"0","summary":"– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 – – KOMET 017 Phase 3 trials to evaluate zif","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180088/35186/en/Kura-Oncology-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","RCC","ASH","BK4139","BK4505","BK4109","LU2463526074.USD","ORR"],"gpt_icon":0},{"id":"2578496817","title":"Exelixis’s Strategic Positioning and Market Prospects Justify Buy Rating Amid RCC Treatment Dynamics","url":"https://stock-news.laohu8.com/highlight/detail?id=2578496817","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578496817?lang=en_us&edition=fundamental","pubTime":"2025-10-28 21:55","pubTimestamp":1761659717,"startTime":"0","endTime":"0","summary":"William Blair analyst Andy Hsieh has maintained their bullish stance on EXEL stock, giving a Buy rating yesterday. Andy Hsieh has given his Buy rat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/exelixiss-strategic-positioning-and-market-prospects-justify-buy-rating-amid-rcc-treatment-dynamics-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/exelixiss-strategic-positioning-and-market-prospects-justify-buy-rating-amid-rcc-treatment-dynamics-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RCC","EXEL"],"gpt_icon":0},{"id":"2576710059","title":"Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576710059","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576710059?lang=en_us&edition=fundamental","pubTime":"2025-10-17 22:00","pubTimestamp":1760709600,"startTime":"0","endTime":"0","summary":"Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows trip","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168712/0/en/Corvus-Pharmaceuticals-Announces-Presentation-of-Interim-Data-from-the-Phase-1b-2-Clinical-Trial-of-Ciforadenant-for-Patients-with-Metastatic-Renal-Cell-Cancer-at-the-European-Soci.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4195","CRVS","PFS","RCC","BK4139","BK4211","ORR"],"gpt_icon":0},{"id":"2575925862","title":"The Ultimate Biotech Stock to Buy With $50 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2575925862","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575925862?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:30","pubTimestamp":1760441400,"startTime":"0","endTime":"0","summary":"This innovative drugmaker still has plenty of upside potential.","market":"nz","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F836689%2Fpatient-sitting-on-hospital-bed.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F836689%2Fpatient-sitting-on-hospital-bed.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/14/the-ultimate-biotech-stock-to-buy-with-50-now/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/14/the-ultimate-biotech-stock-to-buy-with-50-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["RCC","ULTI","BK4213","CRC","LU0266512127.USD","LU0456854461.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}